SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has reached fresh 52-week highs, with traders focused on an expected Q3 earnings report and debating whether the rally reflects BRIUMVI growth expectations or speculative buyout hopes and short covering. The buyout talk remains unconfirmed, and the earnings date has not been officially confirmed.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff amid concerns over a reported Binance security breach is weighing on Strategy shares, with traders debating whether the crypto-market shock signals deeper trouble or a buying opportunity. Concerns about Strategys quarterly results and CFO transition add to the bearish discussion, while some investors expect a rebound.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Weaker 2027 Medicare Advantage star ratings for Aetna are driving concern about lost bonus payments and future margin pressure. Traders are comparing CVSs weakness with Humanas rally on improved ratings, while debating whether the setback is already priced in.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and dividend suspension have driven attention, as the company cited recession-level appliance demand and blamed the Iran war and collapsing consumer confidence. Many traders are alarmed by the worsening outlook and debt burden, while some see the selloff as an overreaction and are buying for a possible rebound.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Traders are focused on a possible update on Corvuss ALPS program around the ASH abstract release and a company call, though the timing and whether the data will be disclosed remain uncertain. Optimism about a potential catalyst is countered by concerns over past delays, managements limited updates and heavy short interest.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

Fubos steep, low-volume decline and repeated new lows dominate the discussion, with many traders saying the selloff lacks a clear company-specific trigger. The community is looking to upcoming earnings and CEO Alisa Bowens strategic plan for clarity, while bears expect further downside and bulls argue for a turnaround or short-covering rebound.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

RASONQUE (daraxonrasib), Revolution Medicines pancreatic cancer therapy, remains the main focus: traders cite its Phase 3 survival results and FDA approval as support for the companys commercial and broader RAS-drug pipeline prospects. Discussion is also divided over valuation and efficacy across KRAS subtypes, with some traders pointing to competition from selective G12D drugs such as Verastems VS-7375.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated NSCLC trial results and shift toward biomarker-selected lung-cancer studies are driving attention: the overall response rate was 24.6%, while a retrospective subgroup showed a stronger signal, but the lung-cancer filing is expected in 2027 and durability remains uncertain. Traders are divided between viewing the selloff as an overreaction to promising precision-treatment data and seeing a narrower, delayed opportunity compounded by managements confusing presentation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal fourth-quarter earnings report is the focus, with traders debating whether its premium valuation can be justified amid memory-cost pressures and concerns about iPhone demand and upgrade cycles. Some expect a sharp post-report drop, while others view Apples restrained AI spending and relative resilience during the tech selloff as supporting its safe-haven appeal.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowheads interim ARO-MAPT resultsshowing substantial tau reduction and supporting subcutaneous delivery of RNAi to the central nervous systemare a major focus. Traders broadly view the data as encouraging platform validation, but many are frustrated that the share price has not reflected the positive results and debate whether the weakness is market-driven or a sell-the-news reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HYSTER-YALE ANNOUNCES DATES OF THIRD QUARTER 2026 EARNINGS RELEASE AND WEBCAST

HYSTER-YALE ANNOUNCES DATES OF THIRD QUARTER 2026 EARNINGS RELEASE AND WEBCAST HYSTER-YALE ANNOUNCES DATES OF THIRD QUARTER 2026 EARNINGS RELEASE AND WEBCASTPR NewswireCLEVELAND, Oct. 29, 2026 CLEVELAND, Oct. 29, 2026 /PRNewswire/ -- Hyster-Yale, Inc. (NYSE: HY) announced today it will release its...

Hyster-Yale (HY) Laps the Stock Market: Here's Why

In the most recent trading session, Hyster-Yale (HY) closed at $29.39, indicating a +1.94% shift from the previous trading day.

Hyster-Yale (HY) Outperforms Broader Market: What You Need to Know

Hyster-Yale (HY) reached $29.8 at the closing of the latest trading day, reflecting a +2.97% change compared to its last close.

Hyster-Yale (HY) Stock Drops Despite Market Gains: Important Facts to Note

In the most recent trading session, Hyster-Yale (HY) closed at $30.1, indicating a -1.86% shift from the previous trading day.

HYSTER-YALE, INC. ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER

HYSTER-YALE, INC. ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER HYSTER-YALE, INC. ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICERPR NewswireCLEVELAND, Oct. 15, 2026CLEVELAND, Oct. 15, 2026 /PRNewswire/ -- Hyster-Yale, Inc. (NYSE: HY) today announced the appointment of Matthew J. Cornell as...

Hyster-Yale (HY) Registers a Bigger Fall Than the Market: Important Facts to Note

In the latest trading session, Hyster-Yale (HY) closed at $31.93, marking a -1.27% move from the previous day.

Hyster-Yale (HY) Outpaces Stock Market Gains: What You Should Know

Hyster-Yale (HY) closed the most recent trading day at $31.94, moving +2.27% from the previous trading session.

Hyster-Yale (HY) Ascends While Market Falls: Some Facts to Note

In the closing of the recent trading day, Hyster-Yale (HY) stood at $31.87, denoting a +2.91% move from the preceding trading day.

Hyster-Yale (HY) Is Considered a Good Investment by Brokers: Is That True?

The average brokerage recommendation (ABR) for Hyster-Yale (HY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Hyster-Yale (HY) Stock Declines While Market Improves: Some Information for Investors

Hyster-Yale (HY) concluded the recent trading session at $32.6, signifying a -2.8% move from its prior day's close.

Hyster-Yale, Inc. engages in the manufacture of lift trucks. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), and Japan and Asia Pasific (JAPIC), Bolzoni, and Nuvera. The Americas include the United States, Canada, Mexico, Brazil, Latin America, and the corporate headquarters. The JAPIC segment involves the operations in the Asia and Pacific regions, China, and the equity earnings. The Bolzoni segment focuses on the distribution and production of attachments, forks, and lift tables marketed under the Bolzoni, Auramo, and Meyer brand names. The Nuvera segment consists of design, manufacture, and sale of hydrogen fuel cell stacks and engines. The company was founded in 1999 and is headquartered in Cleveland, OH.

Hyster Yale Inc - Ordinary Shares - Class A

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$28.49
Prev Close	$29.34
Open	$28.90
Dividend Yield	4.81%
50-Day Moving Average	$32.11
Beta	1.27
Avg. Volume	125,238.63
PE Ratio	-4.34

52-Week High	$41.30
52-Week Low	$26.41
Market Capitalization	$510.84M
EPS (Annual)	-$3.40
Price to Book	1.31
Revenue Per Employee	$502,573.33

Feed

News

Sentiment

Earnings

Fundamentals

Info

HY Fundamentals